Comparison of insulin glargine 300 units/mL and 100 units/mL in adults with type 1 diabetes: Continuous glucose monitoring profiles and variability using morning or evening injections

Diabetes Care

Volumn 40, Issue 4, 2017, Pages 554-560

  Bergenstal, Richard M ^a   Bailey, Timothy S ^b   Rodbard, David ^c   Ziemen, Monika ^d   Guo, Hailing ^e   Muehlen Bartmer, Isabel ^d   Ahmann, Andrew J ^f  

^a INTERNATIONAL DIABETES CENTER   (United States)

^b AMCR Institute   (United States)

^c Biomedical Informatics Consultants LLC   (United States)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^e BDM Consulting Inc   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GLARGINE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; ARTICLE; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; CONTINUOUS GLUCOSE MONITORING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; INFLUENZA; INFORMED CONSENT; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MORNING DOSAGE; NOCTURNAL HYPOGLYCEMIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; AGED; ANALYSIS; BIOASSAY; BLOOD; DIABETES MELLITUS, TYPE 1; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HYPOGLYCEMIA; MALE; METABOLISM; MIDDLE AGED;

ADULT; AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN GLARGINE; MALE; MIDDLE AGED;

EID: 85019629780     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0684     Document Type: Article

References (17)

1. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45:937-948
2. Becker RH, Dahmen R, Bergmann K, LehmannA, Jax T, Heise T. New insulin glargine 300 units z mL21 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units z mL21. Diabetes Care 2015;38:637-643
3. Becker RH, Nowotny I, Teichert L, Bergmann K, Kapitza C. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab 2015;17:261-267
4. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249
5. Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 2009;11:551-565
6. The Diabetes Control and Complications Trial ResearchGroup. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
7. American Diabetes Association. Glycemic targets. Sec. 6. In Standards of Medical Care in Diabetesd2016. Diabetes Care 2015; 38(Suppl. 1):S33-S40
8. Gubitosi-Klug RA; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care 2014;37: 44-49
9. Garber AJ. Will the next generation of basal insulins offer clinical advantages? Diabetes Obes Metab 2014;16:483-491
10. Bohannon NJ. Optimizing insulin regimens in type 1 diabetes. How to help patients get control of their life. Postgrad Med 2003;113: 39-42, 45-48, 54.
11. Bolli GB, Andreoli AM, Lucidi P. Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther 2011; 13(Suppl. 1):S43-S52
12. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971-978
13. Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015;38:2217-2225
14. Bolli GB, Riddle MC, Bergenstal RM, et al.; on behalf of the EDITION 3 study investigators. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015;17:386-394
15. Riddle MC, Bolli GB, Ziemen M, Muehlen- Bartmer I, Bizet F, Home PD; EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014;37:2755-2762
16. Yki-Järvinen H, Bergenstal R, Ziemen M, et al.; EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014; 37:3235-3243
17. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther 2013;15: 198-211